

CAS FORMULATIONS™ (File label CASFORM)

This file is exclusive to STNext.

Subject Coverage	<ul style="list-style-type: none"> • Agrosience * • Coatings • Consumer goods • Cosmetics* 	<ul style="list-style-type: none"> • Food • Materials • Pharmaceuticals* <p>*Areas of focus</p>
File Type	Formulations, Substances	
Features	Thesauri None. Alerts (SDIs) Weekly (default), Biweekly, Monthly CAS Registry Number® Identifiers <input checked="" type="checkbox"/> Page Images <input type="checkbox"/> STN® AnaVist™ <input type="checkbox"/> Keep & Share <input checked="" type="checkbox"/> SLART <input checked="" type="checkbox"/> STN Easy® <input type="checkbox"/> Learning Database <input type="checkbox"/> Structures <input type="checkbox"/>	
Record Content	<ul style="list-style-type: none"> • Bibliographic information and abstracts for patents and journal articles reporting formulations • Information about the ingredients included in formulations, including CAS Registry Numbers. • Information about the experimental activity of formulations • Text extracted from drug product inserts reported in the DailyMed database 	
File Size	More than 4.3 million records (10/2019)	
Coverage	<ul style="list-style-type: none"> • Formulations from English language patents in Subject Coverage areas, 1996 – present • Formulations from selected patents originally published in Chinese, French, German, Japanese, and Korean • Formulations from journal articles, 2014 – present • Drug product inserts from the DailyMed database 	
Updates	Weekly updates (approximately 100,000 records per month)	
Language	English	
Database Producer	Chemical Abstracts Service 2540 Olentangy River Road P.O. Box 3012 Columbus, Ohio 43210-0012 USA Phone: 800-753-4227 (North America) Phone: 614-447-3700 (worldwide) Fax: 614-447-3751 Email: help@cas.org Copyright Holder	

CAS FORMULATIONS

Sources

- Patents
 - Journals
 - Drug Product Inserts
-

User Aids

- Support and training materials are available on the web: www.cas.org
 - Online Helps (HELP DIRECTORY lists all help messages available)
 - STNGUIDE
-

Clusters

None

Related Databases

- CAplus
 - CAS Registry
-

Pricing

Enter HELP COST at an arrow prompt.

Search and Display Field Codes

Fields that allow left truncation are indicated by an asterisk (*). The minimum stem length for left truncation is three (3) characters.

General Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Basic Index * - Contains single words from Title (TI), Abstract (AB), Chemical Name (CN), Formulation Description (FD), Notes fields (Component Note (CNO), Group Note (GNO), Experimental Activity Note (EAN), Product Activity Note (NOTE) and Process Note (NOTE)), and Vocabulary fields (Group (GVO), Component (CVO), Product (PVO), Target (TVO) and Solvent (SVO)). Also includes CAS Registry Numbers. (Left truncation allowed for all text fields other than Chemical Name.)	None (or /BI)	S HERBICIDE S FLUOROCARBON? S THICKENER(W)SOLUTIONS S TOPICAL ANESTHETIC/BI S 1071-83-6	AB, ANTE, CN, CNO, CVO, FD, GVO, PNTE, PVO, SVO, RN, TI, TVO
Abstract *	/AB	S (WATER(1W)OIL)/AB S HIGH TEMP?/AB S (HIV(W)TREAT?)/AB	AB
Accession Number	/AN	S 2019:51550	AN
Attribution (1)	/ATTR	S DAILYMED	ATTR
Author (Inventor) (2)	/AU (or /IN)	S SILBIGER SCOTT M/AU S ANON/AU S O NEILL V?/AU	AU, IN
Component Form Description	/CFR	S POWDER/CFR	CFR
Component Function Description	/CFU	S ENDOTHELIN RECEPTOR A INHIBITOR/CFU	COMPONENT
Component Count (3)	/CMPC	S 1/CMPC	BIB
Chemical Name	/CN	S PROPYLENE GLYCOL/CN	CCN, GCN
Component Name(s) (4)	/CNM	S SORBITOL/CNM S STEAMIC QOS?/CNM	CNM
Component Note*	/CNO	S OLIVE VINEGAR/CNO	COMPONENT
Chemical Name Segment*	/CNS	S METHYLACETALDEHYDE/CNS	CCN, GCN
CAPLUS Accession Number	/CPAN	S 2019:656160	CPAN
Component Vocabulary	/CVO	S METHYLGLYCOSIDES/CVO	COMPONENT
Document Number(CA Abstract Number)	/DN	S 2018:76459/DN	DN
Delivery Route	/DR	S INTRAOCULARLY/DR	PRODUCT
Document Type	/DT	S INSERT/DT S JOURNAL/DT S PATENT/DT	BIB
Experimental Activity Description	/EAD	S HALF-LIFE/EAD	PRODUCT
Experimental Activity Note*	/EAN	S FUNGICIDE/EAN	PRODUCT
Entry Date (3)	/ED	S 20191001/ED	ED
Field Availability	/FA	S CN/FA S TI/FA	---
Formulation Description	/FD	S FERTILIZE?/FD	FD
Feature	/FEA	S POWDER?/FEA	FEA
Formulation Number	/FN	S 1000/FN	FN
Group Description	/GDS	S MONOMER/GDS	GDS
Group Form Description	/GFR	S ABRASIVE PARTICLES/GFR	GROUP

CAS FORMULATIONS

Search Field Name	Search Code	Search Examples	Display Codes
Group Function	/GFU	S ACTIVE AGENT/GFU	GROUP
Group Note*	/GNO	S ETHYL/GNO	GROUP
Group Optionality	/GOP	S MANDATORY/GOP E EXCLUDE/GOP	GROUP
Group Registry Number (6)	/GRN	S 1071-83-6/GRN S 8001-97-6/GRN(L)8028-52-2/GRN	GRN
Group Vocabulary	/GVO	S AVENA SATIVA/GVO	PRODUCT
Group Count (3)	/GRPC	S 4/GRPC	BIB
Inventor (or Author)	/IN (or /AU)	S SILBIGER SCOTT M/AU S ANON/AU S O NEILL V?/AU	IN, AU
Journal Title	/JT	S MUCOSAL IMMUNOLOGY/JT S MUCOSAL IMMUN/JT S IP.COM/JT	BIB
Note	/NOTE	S TORREYA/NOTE	NOTE
Product Final Physical Form	/PF	S OVAL TABLETS/PF	PRODUCT
Product Name Code	/PNC	S GENERIC/PNC	PNC, PRODUCT
Patent Number/Kind Code	/PNK	S CN109498798A/PNK	PN, PI
Product Name Type	/PNM	S BRAND NAME/PNM	PNM, PRODUCT
Product Name Value	/PNV	S GENISTEIN NANOPARTICLES/PNV	PNV, PRODUCT
Product Purpose	/PUP	S ANTI-TUSSIVE/PUP	PRODUCT
Publication Year (patents only) (3,5)	/PY	S 2018/PY	PY, PI
Product Vocabulary	/PVO	S DRUG DELIVERY SYSTEMS/PVO	PVO, PRODUCT
CAS Registry Number	/RN	S 1071-83-6/RN	CRN, GRN
Solvent Vocabulary	/SVO	S BENZOLINE/SVO	SVO, PRODUCT
Target Description	/TGD	S "COUGH AND COLD"/TGD	PRODUCT
Target Relationship	/TGR	S HALLUCINATIONS/TGR	PRODUCT
Target Type	/TGT	S PREVENTS/TGT	PRODUCT
Target Count (3)	/TGTC	S 1/TGTC	PRODUCT
Title*	/TI	S INFLUENZA/TI	TI, BIB
Target Vocabulary	/TVO	S KABUKI SYNDROME/TVO	TVO, PRODUCT
Update (3)	/UP	S 20190923/UD	UP, BIB

- (1) Drug product inserts only.
- (2) AU and IN are aliases. To restrict authors to journals, add J/DT to your search. To restrict to patents, add P/DT.
- (3) Numeric search field that may be searched with numeric operators or ranges.
- (4) Certain product names are represented in CAS FORMULATIONS with registered trademark symbols, trademark symbols, etc. For those items, use truncation while searching to account for the symbol (e.g., S STEAMIC QOS?/CNM)
- (5) For journal articles, crossover to CAplus using the DN or CPAN for PY information. No PY information exists for drug product inserts.
- (6) L proximity for the CAS FORMULATIONS database has been optimized for use in the Group Registry Number field.

Patent Search Fields

Search Field Name	Search Code	Search Examples	Display Codes
Application Date (1)	/AD	S 20190101/AD	AD, PI
Application Number	/AP	S US2018-16229471/AP	AP, PI
Application Year (1)	/AY	S 2018/AY	AY, PI
Inventor (2)	/IN or /AU	S SILBIGER SCOTT M/IN	IN (or AU)
Patent Assignee	/PA	S ALNYLAM/PA	PA
Patent Country	/PC	S US/PC	PN, PI
Patent Number	/PN	S WO2019001567/PN	PN, PI
Patent Number/Kind Code	/PNK	S US 20190083220A1/PNK	PNK, PI
Patent Date (1)	/PD	S 20190101/PD	PD,PI

(1) Numeric search field that may be searched with numeric operators or ranges.

(2) AU and IN are aliases in CAS FORMULATIONS

Super Search Fields

Enter a super search code to execute a search in one or more fields that may contain the desired information. EXPAND may not be used with super search fields. Use EXPAND with the individual field codes instead.

Super Search Field Name	Search Code	Fields Searched	Search Examples	Display Codes
Component Information Group Information	/COMP /GRP	CFU, CNM, CNO, CVO GFU, GDS, GVO	S OVALBUMIN/GRP S SUCROSE/COMP	GRP COMP

DISPLAY and PRINT Formats

Any combination of formats may be used to display or print answers. Multiple codes must be separated by spaces or commas, e.g., D L1 1-5 TI AU; D L1 1-5 TI,AU. The fields are displayed or printed in the order requested.

Hit-term highlighting is available in most fields. In the table-like display of the PI (Patent Information) field, highlighting is shown by an arrow on the right side pointing to the line that includes the hit terms.

Format	Content	Examples
AB	Abstract Text	D TI AB
AD	Application Date	D AD or D PI
AP	Application Number	D AP or D PI
AN	Accession Number (Formulation)	D 1-5 AN
ANTE	Activity Note	D ANTE or D PRODUCT
ATTR (1)	Attribution	D ATTR
AU (IN)	Author (or Inventor) Name	D AU or D IN
AY (2)	Application Year	D AY or D PI
CFR	Component Form Description (CTSV, CFP, CFD)	D CFR
CN	Chemical Name	D CCN GCN
CNM	Component Name	D CNM
CNO	Component Note	D CHEM D CHPR
CNS	Chemical Name Segment	D CCN GCN
CPAN (3)	CAplus Accession Number	D CPAN
RN	CAS Registry Number	D RN D CRN D GRN

CAS FORMULATIONS

DN (3)	Document Number (CA Abstract Number)	D DN
DT	Document Type	D DT

DISPLAY and PRINT Formats (cont.)

EAD	Experimental Activity Description	D PRODUCT
EAN	Experimental Activity Note	D PRODUCT
ED	Entry Date	D ED
FD	Formulation Description	D FD
FN	Formulation Number	D FN
GCN	Group Chemical name	D GCN
GDS	Group Description	D GDS
GFR	Group Form Description (GTSV, GFP, GFD)	D GROUP
GNO	Group Note	D CHEM D CHPR
GRN	Group Registry Number	D GRN
GRPS	Group List	D GRPS
GVO	Group Vocabulary	D GVO
JT	Journal Title	D JT
JTA	Abbreviated Journal Title	D JT
LOC	Location (LCC, LCD, LCP)	D LOC
NOTE	Note	D NOTE
PA	Patent Assignee	D PA
PI	Patent Information Table (PN, PD, AP and AD)	D PI
PNM	Product Name Type (e.g., brand name, generic)	D PNM or D PRODUCT
PNC	Product Name Type Code (e.g., author, brand)	D PNC or D PRODUCT
PNTE	Process Note	D PNTE or D PRODUCT
PNV	Product Name Value	D PNV or D PRODUCT
PVO	Product Vocabulary	D PVO
PY(4)	Publication Year	D PY
SUMM	Group/Component Summary	D SUMM
SVO	Solvent Vocabulary	D SVO
TI	Title	D TI
TVO	Target Vocabulary	D TVO
UP	Update	D UD

(1) Drug product inserts only.

(2) **No hit term highlighting.**

(3) **Appears in records sourced from patents and journals only.**

(4) Appears only in records sourced from patents. For PY information in journals, use the DN or CPAN to retrieve the corresponding record in CAplus.

Predefined DISPLAY and PRINT Formats

Format	Content	Examples
ALL	AN, CPAN, DN, ED, UP, TI, AU, JT, PA, ATTR, DT, PI, FN, FD, GRPS, GRPC, CMPC, TGTC, AB, LCC, LCD, LCP, GNU, GCN, RN, GDS, GNO, GFU, GFR, GMD, GLO, CMPS, GOP, GVO, GAM, CNU, CRN, CNM, CVO, CCN, CAM, CFU, CFR, CMD, CNO, COP, PNM, PNC, PNV, PNU, PUP, FEA, PF, DOS, PVO, DR, EAD, EAN, EAM, TGD, TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, NOTE	D ALL
BIB	AN, CPAN, DN, ED, UP, TI, AU, JT, PA, ATTR, DT, PI, FN, FD, GRPS, GRPC, CMPC, TGTC	D BIB
CHEM	AN, LCC, LCD, LCP, GNU, GCN, GRN, GDS, GNO, GFU, GFR, GMD, GLO, CMPS, GOP, GAM, GDS, CN, CNU, CRN, CNM, CCN, CAM, CFR, CNO, CFU, CMD, COP	D CHEM
CHPR	AN, LCC, LCD, LCP, GNU, GCN, GRN, GDS, GNO, GFU, GFR, GMD, GLO, CMPS, GOP, GVO, GAM, GDS, CN, CNU, CRN, CNM, CVO, CCN, CAM, CFU, CFR, CMD, CMD, COP, PNM, PNC, PNV, PNU, PUP, FEA, PF, DOS, DR, PVO, EAD, EAN, EAM, TGD, TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, NOTE	D CHPR
COMPONENT	CNU, RN, CVO, CNM, CCN, CFU, CFR, CAM, CMD, CNO, COP	D COMPONENT
GROUP	GNU, CMPS, RN, GVO, GFU, GOP, GAM, GDS, CN, GNO, GFR, GMD, GLO	D GROUP
LCHEM	AN, LCC, LCD, LCP, GNU, GCN, GRN, GDS, GNO, GFU, GFR, GMD, GLO, CMPS, GOP, GVO, GAM, GDS, CN, CNU, CRN, CNM, CVO, CCN, CAM, CFR, CNO, CFU, CMD, COP	D LCHEM
PRODUCT	AN, PNM, PNC, PNV, PNU, PUP, FEA, PF, DOS, PVO, DR, EAD, EAN, EAM, TGD, TGT, TGR, TVO, NOTE, RN, AMT, CN, SVO, PNTE	D PRODUCT
SOLVENT	PVO, SVO, PUP, DR, PF, FEA, RN, CN	D SOLVENT
TARGET	PVO, PUP, DR, PF, FEA, TVO, TGD, TGT, TGR	D TARGET

CAS FORMULATIONS**SELECT, ANALYZE, and SORT Fields**

The SELECT command is used to create E-numbers containing terms taken from the specified field in an answer set.

The ANALYZE command is used to create an L-number containing terms taken from the specified field in an answer set.

The SORT command is used to rearrange the search results in either alphabetic or numeric order of the specified field(s).

Field Name	Field Code	ANALYZE/ SELECT (1)	SORT
Abstract	AB	Y	N
Patent Application Date	AD	Y	N
Accession Number	AN	Y	N
Product Activity Note	ANTE	Y	N
Application Patent Number	AP	Y	N
Author Name/ Inventor Name	AU (or IN)	Y	Y
Patent Application Year	AY	Y	Y
Component Form Description	CFR	Y	N
Component Name	CNM	Y	N
CAplus Accession Number	CPAN	Y	Y
Component Registry Number	CRN	Y	N
Component Vocabulary	CVO	Y	N
Document Number (CA Abstract Number)	DN	Y	N
Document Type	DT	Y	Y
Entry Date	ED	Y	Y
Formulation Description	FD	Y	Y
Formulation Number	FN	Y	Y
Group Registry Number	GRN	Y	N
Group Vocabulary	GVO	Y	N
Inventor Name/Author Name	IN (or AU)	Y	Y
Journal Title	JT	Y	Y
Journal Title	JTA	Y	Y
Patent Assignee	PA	Y	N
Patent Publication Date	PD	Y	Y
Patent Number	PN	Y	N
Product Name Type Code	PNC	Y	Y
Product Name	PNM	Y	Y
Process Notes	PNTE	Y	N
Product Name Value	PNV	Y	Y
Publication Year	PY	Y	Y
Registry Number	RN	Y	N
Solvent Vocabulary	SVO	Y	N
Title	TI	Y	Y
Target Vocabulary	TVO	Y	N

Sample Record 1

=> d all

L5 ANSWER 1 OF 594 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:149764 CASFORMULTNS
 CPAN 2018:518948
 DN 168:320861
 ED 16 May 2019
 UP 15 Sep 2019
 TI Ocular film dosage form comprising cyclosporine
 AU Kim, Sang Wook; Kim, Jeong Tae; Yi, Hong Gi
 PA Corepharm Bio Co., Ltd.
 DT ***Patent***

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2018052185	A1	20180322	WO 2017-KR7426	20170712

FN Form 2
 FD Cyclosporine Eye Film Formulation: Drug Delivery Systems or Ophthalmic Agent
 GRPS G1; G2; G3
 GRPC 3
 CMPC 3
 TGTC 1

AB Disclosed is a unit dosage form comprising cyclosporine and being characterized in that the unit dosage form comprises the same amt. as one dose of cyclosporine, that the cyclosporine is dissolved and present in the state of a solid soln., and that the unit dosage form is a film for application to the eye.

LCC Example
 LCD example 1, table 1, 3, 4, 5, test example 1, 2, 3, 4, 5

GROUP G1

GCN Cyclosporin A (9CI, ACI)
 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane, cyclic peptide deriv. (ZCI)
 1: PN: US6686454 SEQID: 1 claimed protein; 7: PN: WO2000002548 PAGE: 30 claimed protein; Abrammune; Antibiotic S 7481F1; Arpimune ME; CICPORAL; Cicloral; Cicloral (antibiotic); Cyclosporin; Ciclosporina Germed; Cipol N; Ciqorin; Consupren; CyclASol; Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl]; Cyclokot; Cyclosporin; Cyclosporine; Cyclosporine A; Cypol-N; Debio088; Equoral; Gengraf; Imusporin; NSC 290193; Neoplanta; Neoral; OL 27-400; Optimmune; Papilock Mini; Ramihyphin A; Restasis; S-Neoral; SDZ-OXL 400; Sandimmun; Sandimmun Neoral; Sandimmun Optoral; Sandimmune; Sandimmune Neoral; Sang-35; SangCyA; Sigmasporin Microoral; Zinograf ME

RN 59865-13-3
 GDS cyclosporin A
 GFU active agent
 CMPS C1

CAS FORMULATIONS

GOP Mandatory

GVO Formulation active agents; Active agents; Formulation active agent;
Formulation active ingredients; Formulation active ingredient; Active
ingredients; Active agent; Active ingredient

COMPONENT C1

RN 59865-13-3

CNM cyclosporin A

CVO Formulation active agents; Active agents; Formulation active agent;
Formulation active ingredients; Formulation active ingredient; Active
ingredients; Active agent; Active ingredient

CCN Cyclosporin A (9CI, ACI)

CCN 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane, cyclic peptide
deriv. (ZCI)

CCN 1: PN: US6686454 SEQID: 1 claimed protein; 7: PN: WO2000002548 PAGE: 30
claimed protein; Abrammune; Antibiotic S 7481F1; Arpimmune ME; CICPORAL;
Cicloral; Cicloral (antibiotic); Ciclosporin; Ciclosporina Germed; Cipol
N; Ciqorin; Consupren; CyclASol; Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-
N-methyl-L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-
dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-
leucyl-L-valyl-N-methyl-L-leucyl]; Cyclokot; Cyclosporin; Cyclosporine;
Cyclosporine A; Cypol-N; Debio088; Equoral; Gengraf; Imusporin; NSC
290193; Neoplanta; Neoral; OL 27-400; Optimmune; Papilock Mini; Ramihyphin
A; Restasis; S-Neoral; SDZ-OXL 400; Sandimmun; Sandimmun Neoral; Sandimmun
Optoral; Sandimmune; Sandimmune Neoral; Sang-35; SangCyA; Sigmasporin
Microoral; Zinograf ME

CAM 0.015 mg

CFU active agent

COP Mandatory

GROUP G2

GCN Ethenol, homopolymer (9CI, ACI)

Vinyl alcohol, polymers (8CI)

100-27H; 100-37H; 100-40H; 1799S; 1R2110; 9P75R; 9X75RS; 9X75SR; A 10 Coex
Test 14; A-T; A-T (vinyl polymer); AH 17; AH 22; AH 24; AH 26; AL 06; AL
6; AL 6 (polymer); AQ 2117; AR; AR (vinyl polymer); AVB 8041W; AW 401; AX
20; AX 300SN; AX 400TNG; AZF 8035; Acroflex 1; Acroflex 2; Aibon AU
7002FL; Airvol 103; Airvol 107; Airvol 107SF; Airvol 125; Airvol 125SF;
Airvol 165; Airvol 165SF; Airvol 166; Airvol 21-205; Airvol 21-25; Airvol
24-203; Airvol 321LA; Airvol 325; Airvol 325SF; Airvol 350; Airvol 350SF;
Airvol 425; Airvol 502

RN 9002-89-5

GDS polyvinyl alcohol

GFU film forming agent

CMPS C2

GOP Mandatory

GVO Film-forming agents; Film formers; Film-forming additives; Film forming
agent; Film former

COMPONENT C2

RN 9002-89-5

CNM polyvinyl alcohol

CVO Film-forming agents; Film formers; Film-forming additives; Film forming
agent; Film former

CCN Ethenol, homopolymer (9CI, ACI)

CCN Vinyl alcohol, polymers (8CI)

CCN 100-27H; 100-37H; 100-40H; 1799S; 1R2110; 9P75R; 9X75RS; 9X75SR; A 10 Coex
Test 14; A-T; A-T (vinyl polymer); AH 17; AH 22; AH 24; AH 26; AL 06; AL
6; AL 6 (polymer); AQ 2117; AR; AR (vinyl polymer); AVB 8041W; AW 401; AX

20; AX 300SN; AX 400TNG; AZF 8035; Acroflex 1; Acroflex 2; Aibon AU 7002FL; Airvol 103; Airvol 107; Airvol 107SF; Airvol 125; Airvol 125SF; Airvol 165; Airvol 165SF; Airvol 166; Airvol 21-205; Airvol 21-25; Airvol 24-203; Airvol 321LA; Airvol 325; Airvol 325SF; Airvol 350; Airvol 350SF; Airvol 425; Airvol 502

CAM 0.69 mg
CFU film forming agent
COP Mandatory

GROUP G3

GCN 1,2-Propanediol (8CI, 9CI, ACI)

(RS)-1,2-Propanediol; (±)-1,2-Propanediol; (±)-Propylene glycol; 1,2-(RS)-Propanediol; 1,2-Dihydroxypropane; 1,2-Propylene glycol; 1000PG; 2,3-Propanediol; 2-Hydroxypropanol; Adeka PG; Adeka Propylene Glycol PG-P; BS 12; DC 403; Dowfrost; HCH 195; Isopropylene glycol; Kilfrost ABC K Plus; Kilfrost ABC-S; Kilfrost DF K Plus; Kollisolv PG; Methylethyl glycol; Methylethylene glycol; Monopropylene glycol; NSC 69860; Nybrine NFP; PG 12; PG-T; PG-T (glycol); ProGlyc 55; Propylene glycol; Propyless; Radianol 4713; Safewing MP-I 1938; Safewing MP-IV 2001; Sirlene; Solar Winter Ban; Solargard P; Susterra PDO; Ucar 35; α-Propylene glycol; dl-Propylene glycol; DL-1,2-Propanediol

RN 57-55-6

GDS Propylene glycol

GFU plasticizer

CMPS C3

GOP Mandatory

GVO Plasticizers; Plasticization agents; Softening agents, plasticizers; Flexibilizers; Plasticizer; Plastics, plasticizers for; Plasticizing agents; Softening agent (polymer); Plasticiser; Plasticisers; Polymer softening agents; Plasticizing agent; Plasticizing materials; Plastifying agent; Flexibilizer; Plastic softening agent; Polymer softening agent; Plastifying agents; Plasticizing material; Plasticization agent; Plasticizers agents; Plasticizer agents; Polymer plasticizing agents; Polymer plasticizing agent; Polymer plasticizer; Structure plasticizing agent; Structure plasticizing agents

COMPONENT C3

RN 57-55-6

CNM Propylene glycol

CVO Plasticizers; Plasticization agents; Softening agents, plasticizers; Flexibilizers; Plasticizer; Plastics, plasticizers for; Plasticizing agents; Softening agent (polymer); Plasticiser; Plasticisers; Polymer softening agents; Plasticizing agent; Plasticizing materials; Plastifying agent; Flexibilizer; Plastic softening agent; Polymer softening agent; Plastifying agents; Plasticizing material; Plasticization agent; Plasticizers agents; Plasticizer agents; Polymer plasticizing agents; Polymer plasticizing agent; Polymer plasticizer; Structure plasticizing agent; Structure plasticizing agents

CCN 1,2-Propanediol (8CI, 9CI, ACI)

CCN (RS)-1,2-Propanediol; (±)-1,2-Propanediol; (±)-Propylene glycol; 1,2-(RS)-Propanediol; 1,2-Dihydroxypropane; 1,2-Propylene glycol; 1000PG; 2,3-Propanediol; 2-Hydroxypropanol; Adeka PG; Adeka Propylene Glycol PG-P; BS 12; DC 403; Dowfrost; HCH 195; Isopropylene glycol; Kilfrost ABC K Plus; Kilfrost ABC-S; Kilfrost DF K Plus; Kollisolv PG; Methylethyl glycol; Methylethylene glycol; Monopropylene glycol; NSC 69860; Nybrine NFP; PG 12; PG-T; PG-T (glycol); ProGlyc 55; Propylene glycol; Propyless; Radianol 4713; Safewing MP-I 1938; Safewing MP-IV 2001; Sirlene; Solar Winter Ban; Solargard P; Susterra PDO; Ucar 35; α-Propylene glycol; dl-Propylene glycol; DL-1,2-Propanediol

CAS FORMULATIONS

CAM 0.075 mL

CFU plasticizer

COP Mandatory

PNM Author designated

PNC author

PNV cyclosporine eye film formulation

PRODUCT PA1

PUP ophthalmic agent

PF Desc: film

PVO Films; Thin films; Two-dimensional films; Film; Thin film; Dry film; Dry films; Two-dimensional film; Protective film; Protective films; Protection film; Ophthalmic agents; Ophthalmic drug; Ophthalmic drugs; Ophthalmic agent; Eye drugs; Eye drug; Eye treatment drug; Eye treatment drugs; Optic drug; Optic drugs; Ophthalmic compositions; Ophthalmic composition

DR ophthalmic

EAD ophthalmological activity

EAN the effect of the film on healthy rabbit eye was evaluated after 24 hours of administration.

EAM Non-Numeric: Observed that there was no visible corneal opacity during the observation period before and 24 hours after the administration, and there was no visible erythema or edema in the conjunctival region., Desc: ophthalmological activity

EAD ophthalmological activity

EAN the effect of the film on 10 corneas of a healthy adult, and sensory evaluation of burning sensation was performed.

EAM Non-Numeric: there is no feeling of burning at all., Desc: ophthalmological activity

EAD disintegration rate

EAN the disintegration rate of the film was evaluated by dissolving film in ***artificial*** ***tears*** .

EAM Single: 9 seconds, Desc: disintegration rate

EAD thickness

EAM Single: 0.010 mm, Desc: thickness

EAD weight

EAM Single: 0.72 mg, Plus/Minus: 0.057 mg, Desc: weight

EAD tensile strength

EAM Single: 26.37 N/mm², Plus/Minus: 1.34 N/mm², Desc: tensile strength

EAD Elongation

EAM Single: 165.21 %, Plus/Minus: 3.93 %, Desc: Elongation

EAD cyclosporine dissolution state

EAN the cyclosporine dissolution state in a film was evaluated.

EAM Non-Numeric: No microscopic traces of drug particles were observed on the surface of the film under the optical microscope and field emission scanning electron microscope., Desc: cyclosporine dissolution state

PRODUCT PA2

PUP drug delivery systems

PVO Drug delivery systems; Drug delivery system; Pharmaceutical delivery systems; Delivery systems; DDS; Pharmaceutical composition; Therapeutic compound delivery system; Drug delivery device; Drug delivery;

Pharmaceutical compn.; Pharmaceutical compositions; Drug delivery devices;
Therapeutic compound delivery systems

TGR delivers

TGT drug

TVO Drugs; Medicaments; Pharmaceutical; Drug; Medicines; Prophylactic agents;
Therapeutic agents; Chemotherapeutic agents; Pharmacological agents;
Chemotherapeutics; Chemotherapy drugs; Medicament; Pharmacological agent;
Prophylactic agent; Therapeutic agent; Chemotherapeutic agent

NOTE cyclosporin A is dissolved or dispersed in a solution composed of polyvinyl alcohol, a solvent and a plasticizer using a magnetic stirrer. the solution was then degassed using an ultrasonic disperser (sonicator) and the solution was cast on a suitable substrate to produce a film. the resulting film was cut to a size of 0.5 x 0.5 cm and the final product was obtained.

Sample Record 2

=> d bib

L5 ANSWER 1 OF 594 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:149764 CASFORMULTNS

CPAN 2018:518948

DN 168:320861

ED 16 May 2019

UP 15 Sep 2019

TI Ocular film dosage form comprising cyclosporine

AU Kim, Sang Wook; Kim, Jeong Tae; Yi, Hong Gi

PA Corepharm Bio Co., Ltd.

DT ***Patent***

PI

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2018052185	A1	20180322	WO 2017-KR7426	20170712

FN Form 2

FD Cyclosporine Eye Film Formulation: Drug Delivery Systems or Ophthalmic Agent

GRPS G1; G2; G3

GRPC 3

CMPC 3

TGTC 1

CAS FORMULATIONS
Sample Record 3

=> d chem

L5 ANSWER 1 OF 594 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:149764 CASFORMULTNS

LCC Example

LCD example 1, table 1, 3, 4, 5, test example 1, 2, 3, 4, 5

GROUP G1

GCN Cyclosporin A (9CI, ACI)

1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane, cyclic peptide deriv. (ZCI)

1: PN: US6686454 SEQID: 1 claimed protein; 7: PN: WO2000002548 PAGE: 30 claimed protein; Abrammune; Antibiotic S 7481F1; Arpimmune ME; CICPORAL; Cicloral; Cicloral (antibiotic); Ciclosporin; Ciclosporina Germed; Cipol N; Ciqorin; Consupren; CyclASol; Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl]; Cyclokot; Cyclosporin; Cyclosporine; Cyclosporine A; Cypol-N; Debio088; Equoral; Gengraf; Imusporin; NSC 290193; Neoplanta; Neoral; OL 27-400; Optimmune; Papilock Mini; Ramihyphin A; Restasis; S-Neoral; SDZ-OXL 400; Sandimmun; Sandimmun Neoral; Sandimmun Optoral; Sandimmune; Sandimmune Neoral; Sang-35; SangCyA; Sigmasporin Microoral; Zinograf ME

RN 59865-13-3

GDS cyclosporin A

GFU active agent

CMPS C1

GOP Mandatory

COMPONENT C1

RN 59865-13-3

CNM cyclosporin A

CCN Cyclosporin A (9CI, ACI)

CCN 1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontane, cyclic peptide deriv. (ZCI)

CCN 1: PN: US6686454 SEQID: 1 claimed protein; 7: PN: WO2000002548 PAGE: 30 claimed protein; Abrammune; Antibiotic S 7481F1; Arpimmune ME; CICPORAL; Cicloral; Cicloral (antibiotic); Ciclosporin; Ciclosporina Germed; Cipol N; Ciqorin; Consupren; CyclASol; Cyclo[L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-L-valyl-(3R,4R,6E)-6,7-didehydro-3-hydroxy-N,4-dimethyl-L-2-aminooctanoyl-L-2-aminobutanoyl-N-methylglycyl-N-methyl-L-leucyl-L-valyl-N-methyl-L-leucyl]; Cyclokot; Cyclosporin; Cyclosporine; Cyclosporine A; Cypol-N; Debio088; Equoral; Gengraf; Imusporin; NSC 290193; Neoplanta; Neoral; OL 27-400; Optimmune; Papilock Mini; Ramihyphin A; Restasis; S-Neoral; SDZ-OXL 400; Sandimmun; Sandimmun Neoral; Sandimmun Optoral; Sandimmune; Sandimmune Neoral; Sang-35; SangCyA; Sigmasporin Microoral; Zinograf ME

CAM 0.015 mg

CFU active agent

COP Mandatory

GROUP G2

GCN Ethenol, homopolymer (9CI, ACI)

Vinyl alcohol, polymers (8CI)

100-27H; 100-37H; 100-40H; 1799S; 1R2110; 9P75R; 9X75RS; 9X75SR; A 10 Coex

October 2019

Test 14; A-T; A-T (vinyl polymer); AH 17; AH 22; AH 24; AH 26; AL 06; AL 6; AL 6 (polymer); AQ 2117; AR; AR (vinyl polymer); AVB 8041W; AW 401; AX 20; AX 300SN; AX 400TNG; AZF 8035; Acroflex 1; Acroflex 2; Aibon AU 7002FL; Airvol 103; Airvol 107; Airvol 107SF; Airvol 125; Airvol 125SF; Airvol 165; Airvol 165SF; Airvol 166; Airvol 21-205; Airvol 21-25; Airvol 24-203; Airvol 321LA; Airvol 325; Airvol 325SF; Airvol 350; Airvol 350SF; Airvol 425; Airvol 502

RN 9002-89-5

GDS polyvinyl alcohol

GFU film forming agent

CMPS C2

GOP Mandatory

COMPONENT C2

RN 9002-89-5

CNM polyvinyl alcohol

CCN Ethenol, homopolymer (9CI, ACI)

CCN Vinyl alcohol, polymers (8CI)

CCN 100-27H; 100-37H; 100-40H; 1799S; 1R2110; 9P75R; 9X75RS; 9X75SR; A 10 Coex

Test 14; A-T; A-T (vinyl polymer); AH 17; AH 22; AH 24; AH 26; AL 06; AL 6; AL 6 (polymer); AQ 2117; AR; AR (vinyl polymer); AVB 8041W; AW 401; AX 20; AX 300SN; AX 400TNG; AZF 8035; Acroflex 1; Acroflex 2; Aibon AU 7002FL; Airvol 103; Airvol 107; Airvol 107SF; Airvol 125; Airvol 125SF; Airvol 165; Airvol 165SF; Airvol 166; Airvol 21-205; Airvol 21-25; Airvol 24-203; Airvol 321LA; Airvol 325; Airvol 325SF; Airvol 350; Airvol 350SF; Airvol 425; Airvol 502

CAM 0.69 mg

CFU film forming agent

COP Mandatory

GROUP G3

GCN 1,2-Propanediol (8CI, 9CI, ACI)

(RS)-1,2-Propanediol; (±)-1,2-Propanediol; (±)-Propylene glycol; 1,2-(RS)-Propanediol; 1,2-Dihydroxypropane; 1,2-Propylene glycol; 1000PG; 2,3-Propanediol; 2-Hydroxypropanol; Adeka PG; Adeka Propylene Glycol PG-P; BS 12; DC 403; Dowfrost; HCH 195; Isopropylene glycol; Kilfrost ABC K Plus; Kilfrost ABC-S; Kilfrost DF K Plus; Kollisol PG; Methylethyl glycol; Methylethylene glycol; Monopropylene glycol; NSC 69860; Nybrine NFP; PG 12; PG-T; PG-T (glycol); ProGlyc 55; Propylene glycol; Propyless; Radianol 4713; Safewing MP-I 1938; Safewing MP-IV 2001; Sirlene; Solar Winter Ban; Solargard P; Susterra PDO; Ucar 35; α-Propylene glycol; dl-Propylene glycol; DL-1,2-Propanediol

RN 57-55-6

GDS Propylene glycol

GFU plasticizer

CMPS C3

GOP Mandatory

COMPONENT C3

RN 57-55-6

CNM Propylene glycol

CCN 1,2-Propanediol (8CI, 9CI, ACI)

CCN (RS)-1,2-Propanediol; (±)-1,2-Propanediol; (±)-Propylene glycol; 1,2-(RS)-Propanediol; 1,2-Dihydroxypropane; 1,2-Propylene glycol; 1000PG; 2,3-Propanediol; 2-Hydroxypropanol; Adeka PG; Adeka Propylene Glycol PG-P; BS 12; DC 403; Dowfrost; HCH 195; Isopropylene glycol; Kilfrost ABC K Plus; Kilfrost ABC-S; Kilfrost DF K Plus; Kollisol PG; Methylethyl glycol; Methylethylene glycol; Monopropylene glycol; NSC 69860; Nybrine NFP; PG 12; PG-T; PG-T (glycol); ProGlyc 55; Propylene glycol; Propyless;

CAS FORMULATIONS

Radianol 4713; Safewing MP-I 1938; Safewing MP-IV 2001; Sirlene; Solar Winter Ban; Solargard P; Susterra PDO; Ucar 35; α -Propylene glycol; dl-Propylene glycol; DL-1,2-Propanediol

CAM 0.075 mL
CFU plasticizer
COP Mandatory

Sample Record 4

=> d chpr

L2 ANSWER 1 OF 73 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:128004 CASFORMULTNS
LCC Article
LCD article page 2

GROUP G3

GCN Cellulose, 2-hydroxypropyl methyl ether (9CI, ACI)
2-Hydroxypropyl methyl cellulose; 2-Hydroxypropyl methyl cellulose ether;
35SK; 40US; 60HD20000; 60MP4000; 60RT50; 60SH06; 60SH100; 60SH4000;
60SH4000F; 60SH5; 65HD50; 65SH-4000; 65SH5; 65SH50; 75HD400; 90SH100;
90SH100000; 90SH15000S; 90SH400; AW 4; Accel R 100; Affinisol 100;
Affinisol 15cP; Affinisol 4M; Affinisol HPMC 100; Affinisol HPMC 100LV;
Affinisol HPMC 4M; AnyCoat-C AN 5; AnyCoat-C AN 6; AnyCoat-C BN 4;
AnyCoat-C CN 10T; Anyaddy AN 50; Anyaddy BN 40H; Anyaddy BN 50; Anyaddy CN
40H; BN 4; Benecel 324; Benecel 363; Benecel 424; Benecel A 15LV; Benecel
A 4C; Benecel E 15; Benecel E 4M; Benecel E 5; Benecel E 50; Benecel K
100LV; Benecel K 100M

RN 9004-65-3
GDS hydroxypropyl methylcellulose
CMPS C3
GOP Mandatory

COMPONENT C3

RN 9004-65-3
CNM hydroxypropyl methylcellulose
CVO Formulation active agents; Active agents; Formulation active agent;
Formulation active ingredients; Formulation active ingredient; Active
ingredients; Active agent; Active ingredient
CCN Cellulose, 2-hydroxypropyl methyl ether (9CI, ACI)
CCN 2-Hydroxypropyl methyl cellulose; 2-Hydroxypropyl methyl cellulose ether;
35SK; 40US; 60HD20000; 60MP4000; 60RT50; 60SH06; 60SH100; 60SH4000;
60SH4000F; 60SH5; 65HD50; 65SH-4000; 65SH5; 65SH50; 75HD400; 90SH100;
90SH100000; 90SH15000S; 90SH400; AW 4; Accel R 100; Affinisol 100;
Affinisol 15cP; Affinisol 4M; Affinisol HPMC 100; Affinisol HPMC 100LV;
Affinisol HPMC 4M; AnyCoat-C AN 5; AnyCoat-C AN 6; AnyCoat-C BN 4;
AnyCoat-C CN 10T; Anyaddy AN 50; Anyaddy BN 40H; Anyaddy BN 50; Anyaddy CN
40H; BN 4; Benecel 324; Benecel 363; Benecel 424; Benecel A 15LV; Benecel
A 4C; Benecel E 15; Benecel E 4M; Benecel E 5; Benecel E 50; Benecel K
100LV; Benecel K 100M

CAM 1 %
CFU active agent
CNO purchased from Aldrich (USA).
COP Mandatory

GROUP G5
GDS P-HEMA-VP polymer
CMPS C1; C2; C4; C5
GOP Mandatory

COMPONENT C1

RN 97-90-5
CNM ethylene glycol dimethacrylate
CVO Crosslinking agents; Crosslinking, agents for; Curing agents; Hardeners; Crosslinking agent; Hardening agents; Crosslinkers; Crosslinking reagents; Linking agents, crosslinking agents; Crosslinking materials; Hardening agents (curing); Curing agent; Cross-linking agent; Cross-linking agents; Crosslinker; Cross-linker; Chemical crosslinking agents; Chemical crosslinking agent; Crosslink agent; Crosslink agents
CCN 2-Propenoic acid, 2-methyl-, 1,1'-(1,2-ethanediyl) ester (ACI)
CCN 2-Propenoic acid, 2-methyl-, 1,2-ethanediyl ester (9CI); Methacrylic acid, ethylene ester (6CI, 8CI)
CCN 1,2-Bis(methacryloyloxy)ethane; 1,2-Ethanediol dimethacrylate; Acryester ED; Acryester EDMA; Blemmer PDE 50; DMM 2; Diglycol dimethacrylate; EG 50; EGDMA; EM 320; Ethanediol dimethacrylate; Ethylene dimethacrylate; Ethylene glycol bis(methacrylate); Ethylene glycol dimethacrylate; Ethylene methacrylate; FA 121M; Fancryl FA 121M; Hi-Cross ED; Hi-Cross ED-P; Light Ester EG; Luvomaxx EDMA-DL 75; NK Ester 1G; NSC 24166; Perkalink 401; Perkalink 401-50D-pd; Perkalink 7401; SR 206; SR 206NS; San Ester EG; Sartomer SR 206; TGM 1; TGM 1 (ester)
CFU crosslinking agent
CNO purchased from Aldrich (USA).
COP Mandatory

COMPONENT C2

RN 78-67-1
CNM azobisisobutyronitrile
CCN Propanenitrile, 2,2'-(1,2-diazenediyl)bis[2-methyl- (ACI)
CCN 2,2'-(1,2-Diazenediyl)bis[2-methylpropanenitrile] (ACI); Propanenitrile, 2,2'-azobis[2-methyl- (9CI); Propionitrile, 2,2'-azobis[2-methyl- (8CI)
CCN 2,2'-Azobis(2-cyanopropane); 2,2'-Azobis(2-methylpropionitrile); 2,2'-Azobis[2-methylpropanenitrile]; 2,2'-Azobis[isobutyronitrile]; 2,2'-Azodiisobutyronitrile; 2,2'-Dimethyl-2,2'-azodipropionitrile; ABN-R; AIBN; AZDH; AZDN; Aceto AZIB; Azobisisobutyronitrile; Azodiisobutyronitrile; ChKhE 57; ChKhZ 57; Genitron AZDN; Genitron AZDN-FF; KB-P 13; KE-P 13; ME 800; NSC 1496; NSC 68042; Perkadox AIBN; Peroxan AZDN; Pianofor An; Porofor ChKhZ 57; Porofor N; V 60; V 60 (polymerization catalyst); Vazo 64; α,α' -Azobis(isobutyronitrile); α,α' -Azodiisobutyric acid dinitrile; α,α' -Azodiisobutyronitrile; N,N'-Azobis(isobutyronitrile); N,N'-Bis(2-cyano-2-propyl)diazene
CFU initiator
CNO purchased from Aldrich (USA).
COP Mandatory

COMPONENT C4

RN 9003-39-8
CNM polyvinylpyrrolidone
CCN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (9CI, ACI)
CCN 2-Pyrrolidinone, 1-vinyl-, polymers (8CI)
CCN 1-Vinyl-2-pyrrolidinone polymer; 1-Vinyl-2-pyrrolidone homopolymer; 1-Vinyl-2-pyrrolidone polymer; 1-Vinylpyrrolidin-2-one homopolymer; 143RP; 40K; 40K (vinyl polymer); 7TS13; 856568G; ACP 10; AT 717; Agent AT 717;

CAS FORMULATIONS

Agrimer 15; Agrimer 30; Agrimer 90; Agrimer ATF; Agrimer K 30; Albigen A; Aldacol Q; Antaron P 804; Antitox Vana; Aqua 65JL; Aqua-Quench EC/WE; Arostit TL 0280; B 7509; BASF-K 85; Bolinan; Cevian A 88036; Creejus K 30; Creejus K 50; Creejus K 90; Cross P.V.P.; Deltaspeed AF; Discol K 30L; Disintex 200; Divergan EF; Divergan F; Divergan RS; Epocros WS 560; Flexithix; Gaftex AE-K 15; Ganex P 804; HY 2; HY 3; Hemodesis; Hemodez; Hemodez N; Hemodez-N

CAM 15 wt %

CNO purchased from Daejung (Korea).

COP Mandatory

COMPONENT C5

RN 868-77-9

CNM 2 hydroxyethyl methacrylate

CCN 2-Propenoic acid, 2-methyl-, 2-hydroxyethyl ester (9CI, ACI)

CCN Methacrylic acid, 2-hydroxyethyl ester (6CI, 8CI); Methacrylic acid, ester with glycol (7CI)

CCN 2-(Methacryloyloxy)ethanol; 2-HEMA; 2-Hydroxyethyl 2-methylprop-2-enoate; 2-Hydroxyethyl methacrylate; Acryester HISS; Acryester HO; Acryester HOMA; Acryl Ester HO; Bisomer HEMA; Bisomer SR; Blemmer E; EB 109; EB 109 (monomer); EM 321; Ethylene glycol methacrylate; Ethylene glycol monomethacrylate; GE 610; Glycol methacrylate; Glycol monomethacrylate; HEMA; HEMA 90; Kayarad 2-HEMA; Light Ester HO; Light Ester HO 250; Light Ester HO 250M; Light Ester HO 250N; Mhoromer BM 903; Mhoromer BM 905; Monomer MG 1; NSC 24180; Rocryl 400; Visiomer HEMA 98; β -Hydroxyethyl methacrylate

CNO purchased from Aldrich

COP Mandatory

PNM Author designated

PNC author

PNV poly-hydroxypropyl methylcellulose-vinylpyrrolidone hydrogel contact lense

PRODUCT PA1

PUP drug delivery system

PF Desc: hydrogel

PVO Hydrogels; Hydrocolloid gels; Hydrogel; Hydrocolloid gel; Contact lenses; Contact lens; Eye, contact lenses; Contacts; Contact; Contact lens material; Drug delivery systems; Drug delivery system; Pharmaceutical delivery systems; Delivery systems; DDS; Pharmaceutical composition; Therapeutic compound delivery system; Drug delivery device; Drug delivery; Pharmaceutical compn.; Pharmaceutical compositions; Drug delivery devices; Therapeutic compound delivery systems

TGR delivers

TGT drug

TVO Drugs; Medicaments; Pharmaceutical; Drug; Medicines; Prophylactic agents; Therapeutic agents; Chemotherapeutic agents; Pharmacological agents; Chemotherapeutics; Chemotherapy drugs; Medicament; Pharmacological agent; Prophylactic agent; Therapeutic agent; Chemotherapeutic agent

TGR treats

TGT eye disease

TVO Eye disease; Eye disorder; Ophthalmopathy; Ocular disease; Eye diseases; Ophthalmic disease; Ocular disorder; Ophthalmologic disease; Ophthalmologic disorder; Ophthalmologic disorders; Ophthalmic disorders; Ophthalmic disorder; Ophthalmic diseases; Ophthalmological disease; Ophthalmological diseases; Ophthalmological disorders; Ophthalmological disorder

Sample Record 5

=> d bib

L2 ANSWER 1 OF 73 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2018:128004 CASFORMULTNS

CPAN 2018:116915

DN 168:380829

ED 16 May 2019

UP 15 Sep 2019

TI pH sensitive soft contact lens for selective drug-delivery

AU Kim, Guenhei; Kim, Hyeok Jung; Noh, Hyeran

JT Macromolecular Research

DT ***Journal***

FN Form 4

FD Poly-Hydroxypropyl Methylcellulose-Vinylpyrrolidone Hydrogel Contact
Lense: Drug Delivery System

GRPS G3; G5

GRPC 2

CMPC 5

TGTC 2

Sample Record 6

=> d bib 2

L3 ANSWER 2 OF 65 CASFORMULTNS COPYRIGHT 2019 ACS on STN

AN 2019:119619 CASFORMULTNS

ED 14 Aug 2019

UP 15 Sep 2019

ATTR DailyMed® is produced by the National Library of Medicine. DailyMed is
a registered trademark of the U.S.National Library of Medicine

DT ***Insert***

FN Form 1

FD Xiidra-Lifitegrast Solution/ Drops: Dry Eye Disease Treatment

GRPS G1; G2; G3; G4; G5; G6

GRPC 6

CMPC 7

TGTC 2

In North America

CAS
STN North America
P.O. Box 3012
Columbus, Ohio 43210-0012 U.S.A.

CAS Customer Center:
Phone: 800-753-4227 (North America)
614-447-3700 (worldwide)
Fax: 614-447-3751
Email: help@cas.org
Internet: www.cas.org

In Europe

FIZ Karlsruhe
STN Europe
P.O. Box 2465
76012 Karlsruhe
Germany
Phone: +49-7247-808-555
Fax: +49-7247-808-259
Email: helpdesk@fiz-karlsruhe.de
Internet: www.stn-international.com

In Japan

JALCI (Japan Association for
International Chemical Information)
STN Japan
Nakai Building
6-25-4 Honkomagome, Bunkyo-ku
Tokyo 113-0021, Japan
Phone: +81-3-5978-3601 (Technical Service)
+81-3-5978-3621 (Customer Service)
Fax: +81-3-5978-3600
Email: support@jaici.or.jp (Technical Service)
customer@jaici.or.jp (Customer Service)
Internet: www.jaici.or.jp